특발성 폐섬유증 치료 시장 규모, 점유율, 동향 분석 보고서 : 약물 종류별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Idiopathic Pulmonary Fibrosis Treatment Market Size, Share & Trends Analysis Report By Drug Class (Pirfenidone, Nintedanib), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

특발성 폐섬유증 치료 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면 특발성 폐섬유증 치료 세계 시장 규모는 2025년부터 2030년까지 6.8%의 CAGR로 2030년까지 54억 6,000만 달러에 달할 것으로 예상됩니다.

기업의 R&D 이니셔티브 증가와 흡연 인구의 급격한 증가가 성장을 견인할 것으로 예상됩니다.

새로운 메커니즘을 가진 제품을 개발하기 위한 제조업체들의 노력이 증가함에 따라 IPF 치료제 시장의 성장이 촉진될 것으로 예상됩니다. 예를 들어, 파이브로젠은 현재 결합조직 성장인자를 표적으로 하는 단클론항체 팸레브르맙(Pamrevlumab)을 개발 중입니다. 펨브렐루맙의 임상 3상 시험은 2019년 상반기에 시작될 예정입니다. 이 약은 미국 식품의약국(FDA)으로부터 패스트트랙 지정을 받았습니다.

고령화는 헬스케어 부문을 포함한 거의 모든 부문에 사회, 경제, 정치적으로 광범위한 영향을 미칠 것으로 예상됩니다. 노인 인구의 증가에 따른 결과로 장기 치료가 필요한 다양한 질병 발생률이 증가합니다. 또한, 중국, 일본 등 미개척 기회가 많은 국가에서 노인 인구의 증가는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.

흡연 인구의 급격한 증가는 시장 성장에 긍정적인 영향을 미칠 수 있는 주요 촉진요인 중 하나입니다. 미국 FDA와 질병통제예방센터(CDC)에 따르면 2018년에는 360만 명 이상의 고등학생과 중학생이 기존 전자담배 사용자로 나타났습니다. 이 숫자는 작년보다 150만 명 증가한 수치입니다. 전자담배의 보급은 IPF의 발병으로 이어질 것으로 예상됩니다.

특발성 폐섬유증 치료 시장 보고서 하이라이트:

• 피르페니돈은 2024년 43.0%의 점유율로 시장을 장악할 것입니다.
• 경구용 약물이 시장을 주도하고 2024년 매출 점유율은 69.3%를 차지할 것으로 예상됩니다. 피르페니돈과 닌테다닙은 주사 요법에 비해 환자의 순응도를 높입니다.
• 병원 약국이 2024년 62.9%의 매출 점유율로 가장 큰 비중을 차지했습니다. 병원은 IPF의 정확한 진단 및 모니터링을 위한 고급 진단 도구를 갖추고 있어 적시에 치료를 쉽게 시작할 수 있기 때문입니다.
• 2024년, 미국이 IPF의 시장 침투율과 인지도가 높아 선두를 차지할 것으로 예상됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 특발성 폐섬유증 치료 시장 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 업계 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 특발성 폐섬유증 치료 시장 : 약물 종류 비즈니스 분석

• 약물 클래스 시장 점유율, 2024년 및 2030년
• 약물 클래스 부문 대시보드
• 시장 규모와 예측 및 동향 분석, 약물 종류별, 2018-2030년
• Pirfenidone
• Nintedanib
• Interferon Gammato1b
• 기타

제5장 특발성 폐섬유증 치료 시장 : 투여 경로 비즈니스 분석

• 투여 경로 시장 점유율, 2024년과 2030년
• 투여 경로 부문 대시보드
• 시장 규모와 예측 및 동향 분석, 투여 경로별, 2018-2030년
• 경구
• 주사

제6장 특발성 폐섬유증 치료 시장 : 유통 채널 비즈니스 분석

• 유통 채널 시장 점유율, 2024년 및 2030년
• 유통 채널 부문 대시보드
• 시장 규모와 예측 및 동향 분석, 유통 채널별, 2018-2030년
• 병원 약국
• 소매 약국
• 기타

제7장 특발성 폐섬유증 치료 시장 : 약물 종류별 지역별 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역 시장 대시보드
• 시장 규모, 예측 동향 분석, 2018년에서 2030년 :
• 북미
  • 국가별, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별, 2018-2030년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 덴마크
  • 스웨덴
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 국가별, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별, 2018-2030년
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 상황

• 참여자 개요
• 기업의 시장 포지션 분석
• 기업 분류
• 전략 매핑
• 기업 개요/상장 기업
  • F. Hoffmann-La Roche Ltd
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Medicinova, Inc
  • Merck &Co., Inc.
  • Galapagos NV
  • Novartis AG
  • Fibrogen, Inc.

ksm

영문 목차

영문목차

Idiopathic Pulmonary Fibrosis Treatment Market Growth & Trends:

The global idiopathic pulmonary fibrosis treatment market size is expected to reach USD 5.46 billion by 2030, registering a CAGR of 6.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing R&D initiatives undertaken by companies and surge in cigarette smoking population are anticipated to boost the growth.

Rise in the initiatives undertaken by manufacturers to develop products with novel mechanisms is anticipated to fuel the IPF treatment market growth. For instance, FibroGen, Inc., is currently developing a drug, pamrevlumab - a monoclonal antibody that targets the connective tissue growth factor. The phase III trials of pamrevlumab are expected to be initiated in the first half of 2019. The drug has received fast track designation from the Food and Drug Administration (FDA).

An aging population can be expected to have far-reaching social, economic, and political implications on nearly all the sectors including the healthcare sector. An associated consequence of an increase in the geriatric population will be an increase in the incidences of various medical conditions requiring long-term care. Moreover, the growing geriatric population base in countries with large untapped opportunities such as China and Japan is anticipated to drive the market growth during the forecast period.

The dramatic increase in cigarette smoking population is one of the major drivers likely to have a positive impact on market growth. According to the U.S. FDA and Centers for Disease Control and Prevention (CDC), in 2018, more than 3.6 million high and middle school students were existing e-cigarette users. The number increased by 1.5 million since the last year. The uptake in the use of e-cigarette is expected to lead to the incidence of IPF.

Idiopathic Pulmonary Fibrosis Treatment Market Report Highlights:

• Pirfenidone dominated the market and accounted for a share of 43.0% in 2024.
• Orally administered medications led the market with a revenue share of 69.3% in 2024. Pirfenidone and nintedanib enhance patient compliance compared to injectable therapies.
• Hospital pharmacies held the largest revenue share 62.9% in 2024, as hospitals are equipped with advanced diagnostic tools for accurate IPF diagnosis and monitoring, facilitating timely treatment initiation.
• U.S. led in 2024 due to high market penetration and high awareness pertaining to IPF

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Route of Administration
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Idiopathic Pulmonary Fibrosis Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Idiopathic Pulmonary Fibrosis Treatment Market: Drug Class Business Analysis

• 4.1. Drug Class Market Share, 2024 & 2030
• 4.2. Drug Class Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 4.4. Pirfenidone
  • 4.4.1. Pirfenidone Market, 2018 - 2030 (USD Million)
• 4.5. Nintedanib
  • 4.5.1. Nintedanib Market, 2018 - 2030 (USD Million)
• 4.6. Interferon Gammato1b
  • 4.6.1. Interferon Gammato1b Market, 2018 - 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Idiopathic Pulmonary Fibrosis Treatment Market: Route of Administration Business Analysis

• 5.1. Route of Administration Market Share, 2024 & 2030
• 5.2. Route of Administration Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 5.4. Oral
  • 5.4.1. Oral Market, 2018 - 2030 (USD Million)
• 5.5. Injectable
  • 5.5.1. Injectable Market, 2018 - 2030 (USD Million)

Chapter 6. Idiopathic Pulmonary Fibrosis Treatment Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2024 & 2030
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Idiopathic Pulmonary Fibrosis Treatment Market: Regional Estimates & Trend Analysis by Drug Class, Route Of Administration, and Distribution Channel

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. U.S. Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Canada Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Framework
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. Mexico Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. UK Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. Germany Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework
    • 7.5.4.3. Competitive Insights
    • 7.5.4.4. France Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework
    • 7.5.5.3. Competitive Insights
    • 7.5.5.4. Italy Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework
    • 7.5.6.3. Competitive Insights
    • 7.5.6.4. Spain Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Norway
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework
    • 7.5.7.3. Competitive Insights
    • 7.5.7.4. Norway Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework
    • 7.5.8.3. Competitive Insights
    • 7.5.8.4. Denmark Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Sweden
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Regulatory Framework
    • 7.5.9.3. Competitive Insights
    • 7.5.9.4. Sweden Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. Japan Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. China Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. India Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. South Korea Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework
    • 7.6.6.3. Competitive Insights
    • 7.6.6.4. Australia Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Framework
    • 7.6.7.3. Competitive Insights
    • 7.6.7.4. Thailand Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. Brazil Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Framework
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Argentina Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. South Africa Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. UAE Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Regulatory Framework
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. Kuwait Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. F. Hoffmann-La Roche Ltd
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Boehringer Ingelheim International GmbH
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Bristol-Myers Squibb Company
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Medicinova, Inc
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Merck & Co., Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Galapagos NV
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Novartis AG
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Fibrogen, Inc.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives

관련자료